EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
14/05/2025
Voltar para busca
Dado oficial do USPTO
ELLIPSES PHARMA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: Estados Unidos
Snapshot rápido
ELLIPSES PHARMA
ST13
US500000088490321Classe
5, 10, 42, 44
Pedido
88490321
Registro
6592661
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
52
Atualização mais recente
21/05/2025
Tipo de marca
Verbal
Classes Nice
5, 10, 42, 44
Data de depósito
26/06/2019
Data de registro
21/12/2021
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
21/12/2021
Última transação
21/05/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Código do desenho
4
Tipo de titular
99
Localização do titular
London, GB
Examinador
OJEYEMI, ASHLEY
Unidade examinadora
O10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Ellipses Pharma Ltd
Representantes
John C. Cain Munck Wilson Mandala, LLP
Classificação técnica
Classes Nice
Classe 5Classe 10Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the treatment of cancer; biological preparations for the treatment of cancer; anti-cancer preparations; anti-cancer drugs; compounds for treating cancer; biopharmaceuticals for the treatment of cancerantibodiesnon-antibody proteinsblood and blood componentsstem cellshormonesblood factorstumour necrosis factors; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-cancer preparations of microbial origin; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations from hormones and antagonists; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; all of the aforesaid for use in oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation to cancer
Classe 10
Medical and surgical apparatus and instrumentsinstruments for diagnosing and treating cancer; medical analysis devicesmedical diagnostic devices for analyzing the presence or extent of cancerfor monitoring cancer treatmentsimmunotherapy cancer treatmentsradiation therapy cancer treatmentschemotherapy cancer treatmentsradiotherapy cancer treatmentstargeted cancer therapy treatments in the bodyfor analyzing the efficacy of cancer treatments; medical imaging apparatusdevices for cancer imaging; medical scanning apparatus namelydevices for scanning for cancer; apparatus for the diagnosis of cancer; apparatus for use in medical analysis for the diagnosis and treatment of cancer; cell counting units for medical diagnostic useelectrical resistance cell countersflow cytometersmicroscopic image analyzers; diagnostic apparatus for medical use for testing cancer cells; all of the aforesaid for use in oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation to cancer
Classe 42
Medical and pharmacological research services; biological researchclinical research in the field of cancer and medical research; Providing an on-line network environment featuring technology that enables users to share data for drug and pharmaceutical research and development; Providing an on-line network environment featuring technology that enables users to share data in the field of the designdevelopment and testing of drugs and pharmaceuticals; Providing scientific and technological servicesscientific researchanalysisdesign relating to oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation to cancer; designdevelopment and testing of drugs and pharmaceuticals for the treatment and/or prevention of cancer; laboratory research into new drugs and pharmaceutical products; pharmaceutical drug development services; research relating into medicines; consultancy services relating to scientific and medical research in the field of cancer and oncology; expert advice relating to drug developmentnamely consulting services in the field of drug development; laboratory analysis in the field of oncology; computer hardware and software design and development in relation to oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation tocancer; computer network services namely providing search engines for obtaining information on a global computer network in relation to oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation tocancer; software hosting serviceshosting software for use by others for use in relation to medical databases and informationin relation to oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation tocancer; software as a service (SAAS) namelyhosting software for use by others for use in relation to medical databases and informationin relation to oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation tocancer; Information Technology (IT) consultancyadvisory and information services relating to a network of medical research professionals in the technology field of medical information networks and databases; scientific advisory servicesproviding scientific informationadvice and consultancy in the field of oncology and cancer clinical trials; scientific research projects and studies in the fields of oncology and clinical trials research; conducting clinical trials for others; clinical research in the field of oncology; clinical research in the field of cancer treatments and pharmaceuticals; providing an online network that features technology that enables users to share data for clinical trials; conducting and compiling data for others for research purposes in the field of treatmentcure and prevention of cancer via an online computer network; development of measuring and testing methods in the field of medicine; evaluation of pharmaceutical drug development services of others to assure compliance with industry standards; pharmaceutical product evaluation; pharmaceutical research services; all of the aforesaid in relation to in oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation to cancer
Classe 44
Medical services; medical consultation services; cancer consultation and treatment servicesmedical diagnosis and treatment of cancer; health care services; health screening services in field of cancer; cancer screening services; managed health care services; pharmaceutical services namelypharmaceutical advice; providing online medical record servicesnamely maintaining personal medical history records and files; advisory and consultancy relating to all of the aforesaid; all of the aforesaid for use in oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation to cancer
Publicações
Histórico de despachos e eventos da marca no USPTO.
52 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
14/05/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
14/05/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
14/05/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
21/11/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
21/11/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
21/11/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
21/11/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
21/12/2021
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
17/11/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
17/11/2021
IUCN
NOTICE OF ALLOWANCE CANCELLED
03/11/2021
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
03/11/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/05/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/03/2021
PUBO
PUBLISHED FOR OPPOSITION
09/03/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
17/02/2021
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
01/02/2021
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
29/01/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
28/01/2021
MREI
NOTICE OF REINSTATEMENT E-MAILED
15/01/2021
ZZZY
PREVIOUS ACTION COUNT WITHDRAWN
08/01/2021
RGIA
REINSTATEMENT GRANTED - INADVERTENTLY ABANDONED
07/01/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
07/01/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/01/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
07/01/2021
MAB2
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
07/01/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
06/01/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/01/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/01/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/01/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
06/01/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/12/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/12/2020
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
21/12/2020
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
23/06/2020
GNFR
FINAL REFUSAL E-MAILED
23/06/2020
CNFR
FINAL REFUSAL WRITTEN
23/06/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/04/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/04/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/04/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/10/2019
GNRT
NON-FINAL ACTION E-MAILED
02/10/2019
CNRT
NON-FINAL ACTION WRITTEN
02/10/2019
DOCK
ASSIGNED TO EXAMINER
17/09/2019
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
09/09/2019
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
05/09/2019
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
01/08/2019
ALIE
ASSIGNED TO LIE
29/07/2019
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
23/07/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/07/2019
NWAP
NEW APPLICATION ENTERED
29/06/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ELLIPSES PHARMA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.